Who Owns Nxera Pharma Company?

Nxera Pharma Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Nxera Pharma?

Nxera Pharma Co., Ltd., formerly Sosei Group Corporation, rebranded on April 1, 2024, following strategic acquisitions. Founded in 1990, the company focuses on GPCR structure-based drug design.

With a global presence and a commitment to innovation, Nxera Pharma is poised to make significant advancements in treating unmet medical needs.

Nxera Pharma is a publicly traded company, meaning its ownership is distributed among various shareholders.

The foundational ownership of Nxera Pharma is rooted in two key entities: Sosei Group Corporation and Heptares Therapeutics. Sosei Group Corporation, established in June 1990, aimed to become Japan's premier global biotechnology leader. Heptares Therapeutics, founded in 2007, specialized in GPCR drug discovery.

Sosei Group's Vision

Founded by Shinichi Tamura, Sosei Group Corporation's initial mission was to establish Japan's first global biotechnology leader. This vision guided its early development and subsequent public offering.

Heptares Therapeutics' Expertise

Heptares Therapeutics was established by a group of scientists focused on pioneering GPCR drug discovery. Their scientific expertise formed the core of the company's innovative approach.

Founding Scientists of Heptares

The scientific founders of Heptares Therapeutics included Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate, and Malcolm Weir. Their collective knowledge was pivotal.

Sosei Group's Public Debut

Sosei Group Corporation became a publicly listed company on the Tokyo Stock Exchange on July 29, 2004. This marked a significant milestone in its journey towards global recognition.

Acquisition of Heptares

In 2015, Sosei Group Corporation acquired Heptares Therapeutics. This strategic acquisition was instrumental in forming the combined entity, Sosei Heptares, enhancing its drug discovery capabilities.

Undisclosed Early Details

Specific details regarding the initial equity split of Sosei Group or early agreements for Heptares Therapeutics, such as vesting schedules, are not publicly available. This includes any early angel investors or friends and family stakes.

The foundational ownership of Nxera Pharma is intrinsically linked to the histories of Sosei Group Corporation and Heptares Therapeutics. Sosei Group Corporation, founded in June 1990 by Shinichi Tamura with the ambition to create Japan's first global biotechnology leader, became publicly traded on the Tokyo Stock Exchange on July 29, 2004. Concurrently, Heptares Therapeutics Ltd., a company focused on GPCR drug discovery, was established in 2007 by scientists Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate, and Malcolm Weir. A pivotal moment in the company's ownership history occurred in 2015 when Sosei Group acquired Heptares Therapeutics, leading to the formation of Sosei Heptares and significantly bolstering its drug discovery capabilities. While the specific initial equity distributions for Sosei Group and early contractual terms for Heptares are not publicly disclosed, the founding visions of global biotechnology leadership and advanced GPCR-targeted drug design were central to their respective origins and the subsequent combined entity's direction. Understanding this ownership history is key to grasping the Growth Strategy of Nxera Pharma.

Key Ownership Milestones

The ownership structure of Nxera Pharma is primarily defined by the integration of two distinct entities, each with its own foundational principles and development trajectory.

• Sosei Group Corporation's establishment in 1990 by Shinichi Tamura.
• Sosei Group's public listing on the Tokyo Stock Exchange on July 29, 2004.
• Heptares Therapeutics Ltd.'s founding in 2007 by a team of scientific experts.
• The acquisition of Heptares Therapeutics by Sosei Group in 2015.
• The subsequent formation of Sosei Heptares, consolidating their capabilities.

Nxera Pharma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Nxera Pharma, formerly Sosei Group Corporation, has seen its ownership evolve significantly, notably with the 2015 acquisition of Heptares Therapeutics and the 2023 acquisition of Idorsia Pharmaceuticals Japan. These strategic moves integrated advanced drug design capabilities and expanded its Japanese operations, culminating in the group's rebranding as Nxera Pharma in April 2024.

The ownership structure of Nxera Pharma as of May 30, 2025, shows a diverse group of stakeholders, with individual investors holding the majority stake. This distribution indicates a broad base of support, while significant holdings by institutional investors and key individuals like Daisuke Gomi suggest a blend of broad public ownership and concentrated influence. The top 17 shareholders collectively control 51% of the company, highlighting a notable concentration of ownership among major entities.

Key Nxera Pharma Stakeholders

Understanding who owns Nxera Pharma is crucial for assessing its corporate governance and strategic direction. The company's ownership has evolved through strategic acquisitions and internal restructuring.

• Individual investors collectively hold 50% of Nxera Pharma.
• Insiders, including management and directors, own 10%.
• Daisuke Gomi is the largest individual shareholder with 9.5%.
• Major institutional investors include JIC Venture Growth Investments Co., Ltd. (6.24%) and Taiyo Pacific Partners L.P. (4.83%).
• The Target Market of Nxera Pharma is influenced by its diverse stakeholder base.

Nxera Pharma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of early 2025, the governance of Nxera Pharma is structured with a Board of Directors comprising both internal executives and independent external directors. Key leadership roles include Chris Cargill as President & CEO and Shinichi Tamura as Chairman. The company is undergoing board transitions, with Tamura, Tomohiro Tohyama, and Kuniaki Kaga slated for retirement.

Nxera Pharma's corporate structure emphasizes robust oversight through committees such as Nomination, Audit, and Compensation, aligning with Japan's Companies Act. While specific details on voting power mechanisms like dual-class shares are not publicly disclosed, the company's public ownership of 50% and the top 17 shareholders holding a combined 51% suggest a standard one-share-one-vote system. This structure indicates that no single entity likely holds a controlling majority, promoting a balanced approach to shareholder influence. There have been no significant reported proxy battles or activist campaigns impacting the company’s decision-making processes. Understanding the Revenue Streams & Business Model of Nxera Pharma provides further context on the company's operational and strategic direction.

Board Oversight and Shareholder Structure

Nxera Pharma's board composition and shareholder distribution aim for strong corporate governance.

• Board includes a mix of executive and independent directors.
• Committees for Nomination, Audit, and Compensation are in place.
• 50% general public ownership indicates a dispersed shareholder base.
• Top 17 shareholders hold 51%, suggesting a significant but not absolute concentration of ownership.
• Focus on independent directors enhances oversight and transparency.

Nxera Pharma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Nxera Pharma, formerly Sosei Group Corporation, has undergone a significant rebranding and integration of its global operations. This strategic move, effective April 1, 2024, unified subsidiaries like Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea under a single brand, reflecting its evolution into an integrated, technology-powered biopharmaceutical entity.

The company's financial performance shows robust growth, with FY2024 revenues reaching JPY 28,835 million (approximately US$190.4 million), a substantial increase driven by the integration of Nxera Pharma Japan and new R&D collaborations. As of December 31, 2024, Nxera Pharma maintained a strong financial position with JPY 32,268 million (approximately US$205.8 million) in cash and cash equivalents, positioning it for anticipated clinical data readouts and strategic advancements in 2025.

Ownership Structure Overview

Individual investors hold the largest portion of Nxera Pharma's ownership at 50%. Institutional investors also maintain a significant presence, with JIC Venture Growth Investments Co., Ltd. being a notable shareholder.

Employee Stakeholder Engagement

Nxera Pharma actively fosters employee ownership, with a high percentage of its permanent staff holding Restricted Stock Units. This initiative underscores a commitment to aligning employee interests with company success.

Recent Corporate Developments

The rebranding to Nxera Pharma Co., Ltd. on April 1, 2024, marked a significant step in unifying its global operations. This followed the strategic acquisition of Idorsia Pharmaceuticals Japan and Korea businesses in July 2023.

Leadership Transition and Future Outlook

The company is navigating a leadership transition with the retirement of founder Shinichi Tamura from the Board of Directors in March 2025. Nxera Pharma remains focused on strategic growth through partnerships and advancing its drug development pipeline, with no current indications of privatization or changes to its public listing status. Understanding the Competitors Landscape of Nxera Pharma provides further context to its strategic positioning.

Nxera Pharma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔